Primary Surgery vs Chemotherapy in Asian Cancer Treatment

Integrating immunotherapy into early-stage gastric cancer (GC) and gastroesophageal junction cancer (GEJC) treatment protocols represents a significant shift from traditional surgical and adjuvant chemotherapy models. While historical standards in regions like Asia often rely on upfront resection followed by adjuvant treatment for stage II-III tumors, emerging clinical data point toward perioperative checkpoint inhibitor integration to improve event-free survival.

In Plain English: The Clinical Takeaway

• Perioperative Immunotherapy: Combining immune checkpoint inhibitors with chemotherapy both before (neoadjuvant) and after (adjuvant) surgery aims to shrink tumors and eliminate microscopic residual disease.
• Stage-Specific Approach: While early-stage disease traditionally relies on surgery, locally advanced stages (Stage II and III) are increasingly targeted with combined systemic therapies to lower recurrence rates.
• Global Variations: Treatment pathways vary between Asian and Western clinical guidelines, reflecting differences in baseline epidemiology, surgical expertise, and regulatory drug approvals by agencies like the FDA and EMA.

Shifting Paradigms in Resectable Gastric and Gastroesophageal Junction Cancers

Historically, the standard of care for resectable gastric cancer (GC) and gastroesophageal junction cancer (GEJC) varied significantly by geography. In many Asian clinical centers, primary surgical resection followed by adjuvant chemotherapy (CTx) remained the entrenched standard for stage II and III tumors. Meanwhile, Western protocols, guided by trials such as MAGIC and more recently CheckMate-649 and KEYNOTE-585, favored perioperative chemotherapy or combined chemo-immunotherapy regimens.

According to recent updates published in the Journal Onkologie, integrating immunotherapy agents—specifically monoclonal antibodies targeting Programmed Death-1 (PD-1)—into early and locally advanced stages is no longer confined to metastatic settings. The underlying mechanism of action involves blocking the PD-1 receptor on T-cells, thereby preventing tumor cells from evading immune surveillance and enhancing the cytotoxic T-lymphocyte response against micro-metastases.

Clinical Trial Evidence and Immunotherapy Efficacy

Clinical investigations into perioperative immunotherapy rely on rigorous, double-blind, placebo-controlled trial designs to establish statistical significance in pathological complete response (pCR) and event-free survival (EFS). Landmark trials such as KEYNOTE-585 and ATTRACTION-5 have shaped how oncologists view the addition of pembrolizumab or nivolumab to standard platinum-based chemotherapy backbones.

Data from these trials indicate that patients with high PD-L1 expression (measured by the Combined Positive Score, or CPS) derive the most substantial benefit from early immune checkpoint inhibition. However, translating these findings into routine clinical practice requires careful patient stratification, as immune-related adverse events (irAEs) can complicate postoperative recovery if inflammatory toxicities affect pulmonary or gastrointestinal tissues.

Comparative Overview of Treatment Paradigms in Resectable GC and GEJC

Treatment Modality	Primary Mechanism	Standard Clinical Setting	Key Regulatory Considerations
Upfront Surgery + Adjuvant CTx	Direct mechanical tumor removal followed by systemic cytotoxic chemotherapy	Traditional Asian protocols for Stage II-III resectable tumors	Established safety profile; lower upfront systemic toxicity
Perioperative Chemo-Immunotherapy	PD-1/PD-L1 blockade combined with cytotoxic cell death before and after resection	Emerging global standard for locally advanced resectable GC/GEJC	Requires biomarker testing (PD-L1 CPS, MSI status); managed irAE risks

Geo-Epidemiological Bridging and Regulatory Access

The integration of immunotherapy into earlier disease stages creates distinct regulatory and logistical challenges across international healthcare systems. The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) evaluate perioperative indications based on event-free survival endpoints, whereas the UK’s National Institute for Health and Care Excellence (NICE) weighs cost-effectiveness models before granting routine National Health Service (NHS) access.

Epidemiological data from the World Health Organization highlights that gastric cancer remains one of the leading causes of cancer-related mortality globally, particularly in East Asia and parts of Eastern Europe. Bridging the gap between regional surgical traditions and modern systemic therapy requires robust biomarker testing infrastructure to ensure patients with mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) tumors receive targeted immunotherapy regimens promptly.

Contraindications & When to Consult a Doctor

While perioperative immunotherapy improves survival metrics for eligible cohorts, it is not appropriate for every patient. Contraindications include pre-existing autoimmune disorders (such as active Crohn’s disease, rheumatoid arthritis, or lupus), severe baseline pneumonitis, and hypersensitivity to monoclonal antibody components. Patients must undergo thorough baseline organ function assessments before initiating combination regimens.

Individuals undergoing treatment who experience new or worsening dyspnea (shortness of breath), persistent diarrhea, severe abdominal pain, unexplained jaundice, or neurological changes must contact their oncology care team immediately. These symptoms can indicate immune-mediated adverse events requiring prompt corticosteroid intervention or temporary cessation of therapy.

Future Trajectory in Oncological Care

The continuous evolution of clinical guidelines reflects a broader transition toward personalized oncology in upper gastrointestinal malignancies. As translational researchers refine predictive biomarkers beyond PD-L1 and MSI status, the medical community moves closer to optimizing risk-benefit ratios for every individual diagnosed with gastric and gastroesophageal junction cancers.

References

• World Health Organization. (2025). Global Cancer Observatory: Gastric Cancer Fact Sheet. Retrieved from WHO Public Health Data.
• National Institutes of Health. (2024). Perioperative Immune Checkpoint Inhibition in Resectable Gastric Cancer. PubMed Central. Retrieved from PubMed Database.
• European Medicines Agency. (2025). Committee for Medicinal Products for Human Use (CHMP) Assessment Reports on Oncology Indications. Retrieved from EMA Official Portal.

Disclaimer: Dr. Priya Deshmukh and Archyde.com provide medical reporting for informational and educational purposes only. This content does not constitute formal medical advice, diagnosis, or treatment. Always seek the advice of a qualified physician or oncologist regarding any health condition or therapeutic intervention.